Gainers
- Sundial Growers SNDL stock rose 9.2% to $0.55 during Tuesday's after-market session. At the close, Sundial Growers's trading volume reached 4.9 million shares. This is 4.7% of its average volume over the last 100 days. The market value of their outstanding shares is at $1.1 billion.
- IN8bio INAB shares moved upwards by 8.21% to $4.15. The market value of their outstanding shares is at $77.8 million.
- Doximity DOCS shares increased by 7.03% to $53.25. Trading volume for this security closed at 374.5K, accounting for 14.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $9.9 billion. As per the press release, Q3 earnings came out today.
- Vaccinex VCNX stock moved upwards by 4.57% to $1.6. The market value of their outstanding shares is at $63.2 million.
- Assertio Holdings ASRT shares increased by 4.16% to $2.75. The market value of their outstanding shares is at $122.7 million.
- Surgalign Holdings SRGA stock rose 3.43% to $0.63. The market value of their outstanding shares is at $92.9 million.
Losers
- Zosano Pharma ZSAN stock fell 33.4% to $0.32 during Tuesday's after-market session. Trading volume for this security closed at 671.8K, accounting for 31.3% of its average full-day volume over the last 100 days. The company's market cap stands at $37.2 million.
- Nuvectis Pharma NVCT stock fell 7.92% to $5.82. The company's market cap stands at $68.7 million.
- Varex Imaging VREX stock fell 4.64% to $25.49. The company's market cap stands at $1.0 billion. As per the news, the Q1 earnings report came out today.
- Dermata Therapeutics DRMA stock declined by 3.65% to $1.32. The company's market cap stands at $10.9 million.
- Durect DRRX shares fell 3.48% to $0.71. The market value of their outstanding shares is at $161.5 million.
- Karyopharm Therapeutics KPTI stock decreased by 3.3% to $7.92. The company's market cap stands at $598.3 million. As per the news, the Q4 earnings report came out today. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in